Akèy › Leksemi mieloïd egi › Oklahoma
Etid klinik pou Leksemi mieloïd egi nan Oklahoma
14 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan Oklahoma.
Vil nan Oklahoma
Tèks ofisyèl etid la (Anglè)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 2
Laj 18 a 59 · Tout sèks · Mizajou Sep 28, 2026 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 2
Laj 18 a 59 · Tout sèks · Mizajou Sep 22, 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 3
6 Months – 21 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT04293562A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Aug 25, 2026 · NCT05886049The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 1/2
Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- OU Health Stephenson Cancer Center, Oklahoma City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT06001788A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Oklahoma Health Science Center, Oklahoma City
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545Pilot Imaging Study of Leukemia
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 1
Laj 4 a 80 · Tout sèks · Mizajou Apr 23, 2026 · NCT03633955A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- OU Health Stephenson Cancer Center, Oklahoma City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT05735184Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 29, 2024 · NCT04905810Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.